

# Board Information Item

---

	<div>Information Packet <input type="checkbox"/></div> <div>Board Agenda Information <input type="checkbox"/></div> <div>Board Agenda Action <input checked="" type="checkbox"/></div> <div>Board Agenda Consent <input type="checkbox"/></div> <div>09/29/2025</div>
<b>Subject:</b>	Consider and Act on a Resolution Related to Bankruptcy Settlements Involving Purdue Pharma, Vote in favor of the Purdue Pharma Bankruptcy Plan, Direct Settlement, and Related Legal Proceedings & Authorize the District to Release Legal Claims as Necessary to Participate in the Purdue Pharma Settlements
<b>Contact Person:</b>	Paula Barbaroux, Chief Operations Officer
<b>Policy/Code:</b>	BAA(LEGAL), BBE(LEGAL)(LOCAL)
<b>Priority and Performance Objective:</b>	Priority 4: Strong Financial Stewardship and Internal System Efficiency Objective 4.1: Transparent Financial Stewardship Objective 4.2: Effective and Efficient District Operations
<b>Summary:</b>	<p>Following the U.S. Supreme Court overturning a previous bankruptcy settlement plan, a \$7.4 billion settlement was reached in 2025 with OxyContin maker Purdue Pharma and its owners, the Sackler family, over their role in the opioid crisis. The bankruptcy settlement is supported by all 50 states, Washington, D.C., and U.S. territories.</p> <p>As a part of that settlement, the bankruptcy plan established the TPP Trust, which will payout based on the value of health plan expenditures from January 1, 2008 to December 31, 2019, on the costs of certain opioid prescriptions, plus the medical costs incurred for certain medical services incurred for a health plan's members that were diagnosed with opioid use disorder after being prescribed an opioid. During the listed time, GCISD operated a self-insured health plan with United Healthcare.</p>

GCISD must consider and vote whether to release legal claims related to the Purdue Pharma opioid litigation. Not releasing claims would mean choosing to potentially pursue litigation (e.g., file a lawsuit) against Purdue Pharma and/or related entities. Releasing legal claims means the District would not be able to later sue Purdue Pharma and/or related entities for claims regarding the opioid crisis. Releasing claims also means the District would likely receive payouts from settlement funds for the benefit of the District.

The recommendation is for the Board of Trustees to authorize the Superintendent and the District's law firm to effectuate all authorizations, plan votes, paperwork necessary to remain a member of the plan, waive its independent legal claims, and obtain or receive a payout in the future.

There are three settlement funds related to the Purdue Pharma bankruptcy for which the District may receive funds in exchange for releasing legal claims: the Estate Settlement, the Direct Settlement, and the TPP Trust. The Estate Settlement is being administered by Kroll (claims and noticing agent). The Texas Attorney General is helping facilitate the Direct Settlement, which is administered by Rubris, Inc. United HealthCare is working with entities like the District to file votes and obtain funds from the TPP Trust. The total amount of funds estimated to be paid from each are as follows: (i) Estate Settlement to Public Schools (\$41 million); (ii) Direct Settlement to Texas, local governments, and subdivisions (\$286 million); and (iii) Third-Party Payors (\$395 million). Because it is unknown how many entities throughout the country will opt into these settlements, payout estimates are uncertain.

GCISD recommends the Board of trustees authorize the Superintendent and the District's law firm to effectuate any authorizations, ballot votes in favor of the bankruptcy settlement plan, waive the District's independent legal claims, and opt-in as needed to remain a member of any plan of which the District might obtain payment in the future.

**Attachments:**

Resolution of the Board of Trustees of GCISD Regarding Purdue Pharma Settlements

**Recommendation:**

The recommendation is for the Board of Trustees to approve the resolution related to bankruptcy settlements involving Purdue Pharma, vote in favor of the Purdue Pharma Bankruptcy Plan, Direct Settlement, and related legal proceedings, authorize the

Superintendent and District's legal counsel to release legal claims as necessary and to effectuate any authorizations, ballot votes, opt-in forms or other documents necessary to participate in the Purdue Pharma settlements.

**RESOLUTION OF THE BOARD OF TRUSTEES OF  
GRAPEVINE-COLLEYVILLE INDEPENDENT SCHOOL DISTRICT  
REGARDING PURDUE PHARMA SETTLEMENTS**

**WHEREAS**, the Board of Trustees (“Board”) of the Grapevine-Colleyville Independent School District (“District”) is authorized by Texas Education Code § 11.151 to govern and oversee the management of the District;

**WHEREAS**, numerous lawsuits have been filed against Purdue Pharma L.P. and related entities, as well as other opioid manufacturers and distributors, regarding the harm caused by the nationwide opioid crisis;

**WHEREAS**, on September 15, 2019 and September 16, 2019, Purdue Pharma L.P. and affiliated debtors filed for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York, jointly administered under Case No. 19-23649, for which the Thirteenth Amended Joint Chapter 11 Plan of Reorganization has been proposed for a vote (“Purdue Pharma Bankruptcy Plan”);

**WHEREAS**, Texas, along with a broad coalition of states and subdivisions, has reached agreements with multiple companies to resolve legal claims for their role in the opioid crisis, including Purdue Pharma and the Sackler family (“Direct Settlement”);

**WHEREAS**, the District is essentially presented with two options: (1) release legal claims regarding the opioid crisis and likely receive settlement funds; or (2) not release legal claims and potentially pursue litigation against those responsible for the opioid crisis, with an uncertain outcome; and

**WHEREAS**, the Board finds that opting into settlements and releasing legal claims regarding the opioid litigation best serves the District’s fiscal resources and its ability to serve students.

**NOW, THEREFORE, BE IT RESOLVED BY THE BOARD OF TRUSTEES OF GRAPEVINE-COLLEYVILLE INDEPENDENT SCHOOL DISTRICT THAT:**

**RESOLVED**, the Board authorizes the District to vote in favor of the Purdue Pharma Bankruptcy Plan, Direct Settlement, and related legal proceedings;

**RESOLVED**, the Board authorizes the District to release legal claims as necessary to participate in the Purdue Pharma Bankruptcy Plan, Direct Settlement, and related legal proceedings;

**RESOLVED**, the Board authorizes and directs the Superintendent, designees, and District’s legal counsel to take all necessary actions and execute any documents required to carry out the vote, participation, and releases as set forth above;

**RESOLVED**, the Board authorizes and directs the Superintendent, designees, and District's legal counsel to take any and all other actions necessary and consistent with this Resolution to protect the District's interests and implement the intent of this Resolution.

**PASSED AND APPROVED** on September 29, 2025 by the Board of Trustees for the Grapevine-Colleyville Independent School District.

By: \_\_\_\_\_

Shannon Braun, Board President

Attest: \_\_\_\_\_

Kathy Florence Spradley, Board Secretary